Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial
Am J Hematol. 2024 Apr 5.
doi: 10.1002/ajh.27304.
Online ahead of print.
1 Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
2 Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
3 Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
4 Practice for Hematology and Oncology UnterEms, Leer, Germany.
5 Practice for Hematology and Oncology Bethanien, Frankfurt/Main, Germany.
6 Practice for Hematology and Oncology Pasing and Fürstenfeldbruck, Munich, Germany.
7 Department of Internal Medicine II, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
8 Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany.